Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.

Histopathology - 1 Jun 2024

Mata Douglas A, Lee Jessica K, Shanmugam Vignesh, Marcus Chelsea B, Schrock Alexa B, Williams Erik A, Ritterhouse Lauren L, Hickman Richard A, Janovitz Tyler, Patel Nimesh R, Kroger Benjamin R, Ross Jeffrey S, Mirza Kamran M, Oxnard Geoffrey R, Vergilio Jo-Anne, Elvin Julia A, Benhamida Jamal K, Decker Brennan, Xu Mina L

Abstract excerpt

AIMS: Liquid biopsy (LBx)-based next-generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue-based NGS is infeasible. METHODS AND RESULTS: We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Hematologic Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Myeloproliferative Disorders

Share to Nucleophosmin

Source

Identifiers

PMID: 38422618
DOI: 10.1111/his.15168

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.PMID 38422618Read ↗

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read ↗

Clinical application of liquid biopsy in cancer patients.Semantic proximity Read ↗

Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer PatientsSemantic proximity Read ↗

Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes.Semantic proximity Read ↗

A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment ResponseSemantic proximity Read ↗

plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid Tumors.Semantic proximity Read ↗

Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.Semantic proximity Read ↗

Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory.Semantic proximity Read ↗

Clinical applications of cell-free DNA-based liquid biopsy analysisSemantic proximity Read ↗

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experienceSemantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.